Press releases | Deinove

16.04.2018

DEINOVE and GREENTECH announce the launch of HEBELYS®, the first cosmetic active ingredient resulting from their collaboration

HEBELYS ® is a natural active ingredient produced by the fermentation of Sphingomonas , a bacterium belonging to the DEINOVE proprietary...

13.04.2018

DEINOVE takes on a whole new dimension with the acquisition of MORPHOCHEM’s clinical-stage antibiotic compound

MORPHOCHEM's MCB3837 antibiotic compound aims to treat severe gastrointestinal infections caused by Clostridium difficile , a priority...

10.04.2018

DEINOVE introduces Phyt-n-Resist®, the first pure phytoene for skincare

Deinove scientific platform has designed an exclusive Deinococcus fermentation process to deliver the first pure Phytoene for application...

28.09.2017

2017 half-year consolidated results: stability of net loss major progress on R&D programs in health, nutrition and cosmetics

Cash position: +€6.6m at June 30, 2017 compared to +€9.3m at December 31, 2016. Half-year net loss of DEINOVE Group (composed of DEINOVE...

16.05.2017

Shareholders’ meeting of May 16, 2017: Hervé BRAILLY joins the Board of Directors

Hervé Brailly, co-founder and executive of Innate Pharma SA [IPH], one of the world's leading immuno-oncology specialists and one of the...

30.03.2017

2016 annual results: Strategic focus on track – promising results in the fields of health, nutrition and cosmetics

Cash position of €9.3 million, and net loss down 1% to €6.3 million Strategic focus on high value-added applications in the healthcare,...

23.01.2017

DEINOVE strengthens its Board in line with its strategic focus

Four directors of international standing and experts in pharmaceutical industry and antibiotics join the Board of Directors: Bernard Fanget...

11.01.2017

DEINOVE announces its financial calendar for 2017

DEINOVE (Alternext Paris: ALDEI), a biotech company that discovers, develops and produces high-value compounds from rare bacteria, notably...

05.01.2017

Completion of the contribution in kind: DEINOVE now holds 100% of DEINOBIOTICS

Completion of the contribution in kind of DEINOBIOTICS’ shares to DEINOVE which now holds 100% of its subsidiary Consequential DEINOVE’s...

29.09.2016

2016 interim results: Stability of net loss | Strategic refocusing on carotenoids and antibiotics

Cash position: +€10.4 M at June 30, 2016 compared to +€12.4 M at December 31, 2015 Stability of interim net loss at -€3.1M Strategic...

1
2
3
4
5
6
7
next ›
last »